203186-96-3

Basic information

• Product Name: 1-BOC-4-AMINO-PIPERIDINE-4-METHANOL
• Synonyms: 1-BOC-4-AMINO-PIPERIDINE-4-METHANOL;tert-butyl 4-amino-4-(hydroxymethyl)piperidine-1-carboxylate;1-Boc-4-amino-4-(hydroxymethyl)piperidine
• CAS NO: 203186-96-3
• Molecular Formula: C₁₁H₂₂N₂O₃
• Molecular Weight: 230.306
• Mol File: 203186-96-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 335.3±27.0 °C(Predicted)
• Appearance: /
• Density: 1.100±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 14.94±0.10(Predicted)
• CAS DataBase Reference: 1-BOC-4-AMINO-PIPERIDINE-4-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-AMINO-PIPERIDINE-4-METHANOL(203186-96-3)
• EPA Substance Registry System: 1-BOC-4-AMINO-PIPERIDINE-4-METHANOL(203186-96-3)

Safety Data

• Hazardous Substances Data: 203186-96-3(Hazardous Substances Data)

Usage

General Description

1-BOC-4-AMINO-PIPERIDINE-4-METHANOL is a chemical compound with potential applications in the field of organic synthesis. It is a derivative of piperidine, a heterocyclic amine commonly used in the pharmaceutical industry. The compound contains a BOC (tert-butyloxycarbonyl) protecting group, which can be selectively removed to expose the amine functionality, making it useful for building more complex organic molecules. Additionally, the presence of the hydroxyl group in the compound provides the potential for further derivatization and functionalization. Overall, 1-BOC-4-AMINO-PIPERIDINE-4-METHANOL is a versatile chemical building block with potential in drug discovery and other areas of chemical research.

Upstream product

• 1187321-31-8 4-benzyloxycarbonylaminopiperidine-1,4-dicarboxylic acid-1-tert-butyl ester-4-ethyl ester 
• 1093214-64-2 1-(tert-butoxycarbonyl)-4-(ethoxycarbonyl)piperidine-4-carboxylic acid 
• 1187321-32-9 4-aminopiperidine-1,4-dicarboxylic acid-1-tert-butyl ester-4-ethyl ester 
• 183673-71-4 4-amino-1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid 

Downstream Products

• 917834-41-4 tert-butyl 4-(benzyloxycarbonylamino)-4-(hydroxymethyl)piperidine-1-carboxylate 
• 1187321-35-2 (4-fluoromethylpiperidin-4-yl)carbamic acid benzyl ester 
• 1187321-34-1 tert-butyl 4-(benzyloxycarbonylamino)-4-(fluoromethyl)piperidine-1-carboxylate 

Relevant articles and documents

Discovery of 3-chlorobenzyl-linked 1,9-diazaspiro[5.5]undecane derivatives, a lead for dengue virus type 2 infection

Dengue virus poses a serious worldwide health threat with up to 400 million infections occurring annually in over 100 countries. Currently, there are no specific therapeutics available, and the only licensed vaccine is used to mitigate the risk of hospitalization in immunologically naive individuals. In the current work, for the first time we are reporting dengue virus type 2 (DENV2) inhibitory activity in newly designed 3-chlorobenzyl-linked 1,9-diazaspiro[5.5]undecane derivatives. Compounds with substitutions featuring 2-methylbenzyl (SPO-6, EC50 = 11.43 ± 0.87 μM), 4-bromobenzyl (SPO-7, EC50 = 14.15 ± 0.50 μM), and 4-cyanobenzyl (SPO-13, EC50 = 20.77 ± 1.92 μM) groups and the antiviral drug ribavirin (IC50 = 50.9 ± 18 μM, J. Gen. Virol., 2006, 87, 1947–1952) were found to be potent against DENV2 in a cell-based assay. Docking calculations identified NS5-methyltransferase as the most probable target for this series of compounds. Molecular dynamics simulations of NS5-methyltransferase reproduced the experimental binding affinity findings by yielding ΔGbind values that predicted SPO-6 to possess the most favorable binding energy of ?27.2 ± 3.9 kcal mol?1 compared with SPO-7, SPO-13 and ribavirin with ?22.5 ± 4.7, ?22.5 ± 4.6 and ?20.0 ± 4.6 kcal mol?1, respectively. In addition, based on Lipinski's rule of five, SPO-6 was found to be non-toxic and possessed a better drug-likeness score (5.87) in comparison with the standard drug ribavirin (1.72).

COMPOUNDS

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.

NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES

A compound of formula (I) or a tautomeric form, regioisomer, stereoisomer, solvate, N-oxide or pharmaceutically acceptable salts thereof; wherein 'a' - is selected from the group consisting of substituted or unsubstituted heterocycloalkyl ring and substituted or unsubstituted carbohydrate moiety y is a member selected from -O-, -CO-, -S02-, aminoalkyl or formula (II) wherein, Rw is hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; x is a member selected from -0-, -S-, -SO-, -S02-, CONR10, NR10CO and -NRd-, or x and y together represent a chemical bond; Z is selected from -CH-, -N-. t is an integer selected from O to 4; with the provisos that when 'a' is substituted or unsubstituted heterocycloalkyl ring then 't' is not O and when y = -CO-, x is not NRd.